PKU (phenylketonuria) is treated primarily through a strict low-protein diet that limits phenylalanine, an amino acid the body can’t properly break down. Treatment starts within the first days of life and continues lifelong, with the goal of keeping blood phenylalanine levels below 360 μmol/L (about 6 mg/dL). For some patients, medications can help the body process phenylalanine more effectively, reducing how restrictive the diet needs to be.
How PKU Is Detected
Every baby born in the United States is screened for PKU through a simple blood test, typically done a day or two after birth once the baby has started feeding. If that initial screen comes back abnormal, additional blood and urine tests confirm the diagnosis. Because treatment works best when it starts early, most babies with PKU are on a managed diet within the first week or two of life. Early and consistent treatment prevents the intellectual disability, seizures, and behavioral problems that untreated PKU causes.
The Low-Phenylalanine Diet
Phenylalanine is found in nearly all protein-containing foods, so the PKU diet is one of the most restrictive therapeutic diets in medicine. The foods that are off-limits include meat, poultry, fish, eggs, dairy, nuts, seeds, soy products, legumes, and whole grains like oats, quinoa, and wheat. Even protein bars and protein powders are excluded. What remains are mostly fruits, some vegetables, and specially manufactured low-protein versions of bread, pasta, and rice.
Because cutting out so much protein would leave dangerous nutritional gaps, people with PKU drink a specialized medical formula every day. These formulas supply all the amino acids the body needs for growth and cell repair, minus the phenylalanine. They also contain vitamins and minerals that are hard to get from the restricted diet alone. Most people with PKU split their formula into several servings throughout the day. The taste and texture of these formulas have improved over the years, but many patients still find them unpleasant, which is one of the biggest barriers to staying on treatment long-term.
A dietitian who specializes in metabolic disorders works with each patient to calculate exactly how much phenylalanine they can safely eat each day. That allowance varies from person to person depending on how much enzyme activity they retain. Regular blood tests, sometimes weekly for infants and monthly or quarterly for older patients, track whether phenylalanine levels are staying in the target range.
Medication for Responsive Patients
Some people with PKU respond to a medication called sapropterin, a synthetic version of a natural compound the body uses to activate the enzyme that breaks down phenylalanine. In people with certain genetic variants of PKU, this medication can coax the underperforming enzyme into working more effectively. The result is that blood phenylalanine drops, and the patient can tolerate more protein in their diet.
Not everyone benefits, though. In clinical trials testing adults with PKU, about 20% saw a meaningful reduction in blood phenylalanine at a standard dose. In children aged 4 to 12 tested at a higher dose, the response rate was better: roughly 56% qualified as responders. Whether sapropterin works for a given individual depends on their specific genetic mutation, so doctors typically run a trial period of about a week to see if blood levels drop before committing to long-term use. Even for responders, the diet doesn’t go away entirely. It becomes less restrictive, but monitoring continues.
Enzyme Substitution Therapy
For adults with PKU whose levels remain difficult to control with diet and sapropterin, a second medication offers a different approach. Rather than boosting the body’s own defective enzyme, this injectable therapy introduces a substitute enzyme derived from a different biological source that can break down phenylalanine through an alternative pathway. It’s given as a self-administered injection under the skin, typically in the thigh or abdomen.
This treatment can be highly effective at lowering phenylalanine, sometimes enough to allow a nearly unrestricted diet. But it comes with a serious trade-off: a significant risk of allergic reactions, including anaphylaxis, which can occur at any point during treatment. Because of this risk, the first dose is given under medical supervision with at least 60 minutes of observation afterward. Every patient prescribed this medication must carry an epinephrine auto-injector at all times, and both the patient and a designated observer need training in recognizing and responding to severe allergic reactions. Many patients also take antihistamines or fever reducers before each injection to reduce milder reactions like joint pain and skin irritation.
PKU and Pregnancy
Pregnancy adds urgent stakes to phenylalanine control. High maternal phenylalanine levels are toxic to the developing fetus even when the baby doesn’t have PKU. Without strict dietary control, the risks are staggering: a 92% chance of developmental delays, a 73% chance of an abnormally small head (microcephaly), and a 12% risk of congenital heart defects, along with growth delays and seizures.
The American College of Obstetricians and Gynecologists recommends that women with PKU bring their phenylalanine levels below 6 mg/dL for at least three months before conception and maintain levels between 2 and 6 mg/dL throughout pregnancy. This often means returning to a much stricter version of the diet than the person may have been following as an adult, with very frequent blood monitoring. The fetal brain and heart are particularly vulnerable, making preconception planning essential rather than optional.
Insurance and Cost Barriers
One of the most persistent challenges of PKU treatment has nothing to do with biology. The medical formulas that people with PKU depend on are expensive, often costing hundreds of dollars per month, and insurance coverage is inconsistent. Some states mandate coverage for metabolic formulas, but others don’t, and the level of coverage varies widely even among plans within the same state.
Legislation called the Medical Nutrition Equity Act has been introduced in Congress to require both public and private insurance to cover medically necessary foods prescribed for inherited metabolic disorders like PKU. The bill’s sponsors argue that medical nutrition is as critical for these patients as prescription drugs. Until coverage becomes universal, many families navigate a patchwork of state laws, insurance appeals, and manufacturer assistance programs to afford the formulas that keep phenylalanine in a safe range.
Why Lifelong Treatment Matters
PKU was once considered a childhood condition, with some doctors relaxing dietary restrictions after adolescence. That thinking has changed. Current guidelines from the American College of Medical Genetics and Genomics recommend lifelong maintenance of blood phenylalanine at or below 360 μmol/L for the best intellectual outcomes. Adults who stop treatment often experience difficulty concentrating, mood changes, anxiety, and slower processing speed, symptoms that can improve when they resume dietary control.
Staying on the PKU diet as an adult is genuinely difficult. Social eating, travel, and the simple fatigue of decades of restriction lead many adults to loosen their diets. The availability of medications that lower phenylalanine has helped some patients maintain better control with less dietary burden, but for most people with PKU, the low-protein diet and medical formula remain the foundation of treatment from the newborn period onward.